|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
|
ES2337127T3
(es)
|
2000-11-02 |
2010-04-21 |
Ajinomoto Co., Inc. |
Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
|
|
CA2429833A1
(en)
*
|
2000-11-30 |
2002-06-06 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
|
|
MXPA03005923A
(es)
|
2000-12-28 |
2004-01-26 |
Kissei Pharmaceuticals Co Ltd |
Derivados de glupopiranosiloxipirazol y su uso en medicinas.
|
|
WO2002068439A1
(fr)
|
2001-02-26 |
2002-09-06 |
Kissei Pharmaceutical Co., Ltd. |
Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
|
|
US7294618B2
(en)
|
2001-02-27 |
2007-11-13 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxypyrazole derivatives and medicinal use thereof
|
|
WO2002080935A1
(en)
|
2001-04-04 |
2002-10-17 |
Ortho Mcneil Pharmaceutical, Inc. |
Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
|
|
US20030045553A1
(en)
*
|
2001-04-04 |
2003-03-06 |
Bussolari Jacqueline C. |
Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
|
|
JP4292570B2
(ja)
|
2001-04-27 |
2009-07-08 |
味の素株式会社 |
N−置換ピラゾール−o−グリコシド誘導体及びそれらを含有する糖尿病治療薬
|
|
EP1400529A4
(en)
|
2001-05-30 |
2007-12-19 |
Kissei Pharmaceutical |
GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
|
|
US20030087843A1
(en)
*
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
|
US7956041B2
(en)
*
|
2002-04-26 |
2011-06-07 |
Ajinomoto Co., Inc. |
Prophylactic and therapeutic agent of diabetes mellitus
|
|
AR040588A1
(es)
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
|
ATE485818T1
(de)
*
|
2002-07-30 |
2010-11-15 |
Karykion Inc |
Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
|
|
BRPI0313290B1
(pt)
*
|
2002-08-08 |
2016-12-06 |
Kissei Pharmaceutical |
derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
|
|
ZA200501094B
(en)
*
|
2002-08-08 |
2006-10-25 |
Kissei Pharmaceutical |
Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
|
|
UA77300C2
(en)
|
2002-08-09 |
2006-11-15 |
Taisho Pharmaceutical Co Ltd |
5-thio-?-d-glucopyranoside derivatives and pharmaceutical composition for treating diabetes
|
|
JP2004137245A
(ja)
|
2002-08-23 |
2004-05-13 |
Kissei Pharmaceut Co Ltd |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
|
CN100413878C
(zh)
*
|
2002-08-23 |
2008-08-27 |
橘生药品工业株式会社 |
吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
|
|
AU2003262262A1
(en)
*
|
2002-08-27 |
2004-03-19 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
|
|
WO2004019926A1
(ja)
*
|
2002-08-30 |
2004-03-11 |
Mitsubishi Pharma Corporation |
心不全の予防及び/又は治療剤
|
|
CA2500873C
(en)
|
2002-10-04 |
2012-01-17 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
|
|
EP1568380A4
(en)
*
|
2002-12-04 |
2009-10-21 |
Kissei Pharmaceutical |
PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA
|
|
WO2004058790A1
(ja)
*
|
2002-12-25 |
2004-07-15 |
Kissei Pharmaceutical Co., Ltd. |
含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
|
CA2523083C
(en)
|
2003-04-25 |
2014-07-08 |
Gilead Sciences, Inc. |
Antiviral phosphonate analogs
|
|
US7576064B2
(en)
*
|
2003-06-20 |
2009-08-18 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, drug composition containing the same and production intermediate therefor
|
|
US20050113314A1
(en)
*
|
2003-08-29 |
2005-05-26 |
Fong Benson M. |
Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
|
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
|
WO2005012326A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Tanabe Seiyaku Co., Ltd. |
Novel compounds having inhibitory activity against sodium-dependant transporter
|
|
UA86042C2
(en)
|
2003-08-01 |
2009-03-25 |
Янссен Фармацевтика Н.В. |
Substituted indazole-o-glucosides
|
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
|
JP4520988B2
(ja)
*
|
2003-08-26 |
2010-08-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシルオキシ−ピラゾール、これらの化合物を含む医薬組成物、これらの使用及びこれらの調製方法
|
|
US7838552B2
(en)
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
US7803838B2
(en)
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
JP4880591B2
(ja)
|
2004-06-04 |
2012-02-22 |
テバ ファーマシューティカル インダストリーズ リミティド |
イルベサルタンを含む医薬組成物
|
|
JP5010918B2
(ja)
*
|
2004-07-21 |
2012-08-29 |
キッセイ薬品工業株式会社 |
肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
|
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
|
PL216369B1
(pl)
|
2004-07-27 |
2014-03-31 |
Gilead Sciences |
Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
|
|
WO2006034435A2
(en)
*
|
2004-09-21 |
2006-03-30 |
Point Therapeutics, Inc. |
Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
|
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
|
TWI365186B
(en)
|
2005-01-31 |
2012-06-01 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
|
CA2600372C
(en)
*
|
2005-03-17 |
2013-04-02 |
Kissei Pharmaceutical Co., Ltd. |
Process for production of glucopyranosyloxypyrazole derivative
|
|
CA2621269A1
(en)
*
|
2005-07-22 |
2007-01-25 |
Boehringer Ingelheim International Gmbh |
Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes
|
|
UY29694A1
(es)
*
|
2005-07-28 |
2007-02-28 |
Boehringer Ingelheim Int |
Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
|
|
CN101243050B
(zh)
*
|
2005-08-31 |
2012-07-04 |
霍夫曼-拉罗奇有限公司 |
吡唑啉酮衍生物
|
|
UY30082A1
(es)
|
2006-01-11 |
2007-08-31 |
Boehringer Ingelheim Int |
Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
|
|
CN100384416C
(zh)
*
|
2006-03-20 |
2008-04-30 |
杨军 |
一种用于治疗心血管疾病的药物组合物
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
TWI418556B
(zh)
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
|
TWI499414B
(zh)
*
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
|
WO2008070609A1
(en)
*
|
2006-12-04 |
2008-06-12 |
Janssen Pharmaceutica N.V. |
Thienyl-containing glycopyranosyl derivatives as antidiabetics
|
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
|
BRPI0719941A2
(pt)
|
2006-12-06 |
2014-04-22 |
Smithkline Beecham Corp |
Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica
|
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
|
NZ600110A
(en)
|
2007-09-10 |
2013-03-28 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt
|
|
CA2709530C
(en)
*
|
2007-12-27 |
2016-02-23 |
Kissei Pharmaceutical Co., Ltd. |
Monosebacate of pyrazole derivative
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
|
JP5620376B2
(ja)
|
2008-07-08 |
2014-11-05 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hiv阻害剤化合物の塩
|
|
AP2728A
(en)
*
|
2008-08-28 |
2013-08-31 |
Pfizer |
Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
|
|
WO2010045529A2
(en)
*
|
2008-10-16 |
2010-04-22 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
|
US20100113583A1
(en)
*
|
2008-10-16 |
2010-05-06 |
Aronne Louis J |
Combination therapies for the treatment of obesity
|
|
US20100113604A1
(en)
*
|
2008-10-16 |
2010-05-06 |
Aronne Louis J |
Combination therapies for the treatment of obesity
|
|
US20100113603A1
(en)
*
|
2008-10-16 |
2010-05-06 |
Aronne Louis J |
Combination therapies for the treatment of obesity
|
|
WO2010045522A2
(en)
*
|
2008-10-16 |
2010-04-22 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20100167989A1
(en)
*
|
2008-10-23 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
Isopropoxyphenylmethyl inhibitors of sglt2
|
|
HUE050287T2
(hu)
|
2009-02-13 |
2020-11-30 |
Boehringer Ingelheim Int |
SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai
|
|
EP2416797A4
(en)
*
|
2009-04-10 |
2013-04-24 |
Amylin Pharmaceuticals Llc |
AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
|
|
EP2424543A4
(en)
*
|
2009-04-30 |
2012-10-17 |
Glaxosmithkline Llc |
CHEMICAL PROCESS
|
|
WO2010151503A2
(en)
*
|
2009-06-25 |
2010-12-29 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
|
WO2010151565A2
(en)
*
|
2009-06-26 |
2010-12-29 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
|
WO2011008490A2
(en)
*
|
2009-06-29 |
2011-01-20 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
US8772512B2
(en)
|
2009-07-10 |
2014-07-08 |
Janssen Pharmaceutica Nv |
Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
|
|
WO2011009115A2
(en)
*
|
2009-07-17 |
2011-01-20 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
|
US20110082407A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Aronne Louis J |
Combination Therapies for the Treatment of Obesity
|
|
PH12012500698A1
(en)
*
|
2009-10-14 |
2016-05-27 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
DK2496583T3
(en)
|
2009-11-02 |
2015-02-02 |
Pfizer |
Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
|
|
KR20130028058A
(ko)
*
|
2010-02-03 |
2013-03-18 |
엠이에이치 어소시에이츠, 인코포레이티드 |
선택적 및 생활성 동배체로서의 다수 치환된 플루오로메탄류
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US20140088027A1
(en)
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
|
ES2596291T3
(es)
|
2010-05-11 |
2017-01-05 |
Janssen Pharmaceutica, N.V. |
Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
|
|
CN103153288B
(zh)
*
|
2010-07-09 |
2017-02-15 |
詹姆斯·特林卡·格林 |
用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8933121B2
(en)
*
|
2011-01-10 |
2015-01-13 |
Sami Labs Limited |
Anti-obesity potential of Calebin A
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
CN103596944B
(zh)
|
2011-04-13 |
2017-02-22 |
詹森药业有限公司 |
可用作sglt2的抑制剂的化合物的制备方法
|
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
US20130137646A1
(en)
|
2011-06-03 |
2013-05-30 |
Boehringer Ingelheim International Gmbh |
Methods of treatment, pharmaceutical compositions and uses thereof
|
|
RU2500407C2
(ru)
*
|
2012-02-20 |
2013-12-10 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации |
Средство, обладающее мочегонным действием
|
|
RU2517091C2
(ru)
*
|
2012-02-20 |
2014-05-27 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации) |
Средство, обладающее мочегонным действием
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
|
PT2981269T
(pt)
|
2013-04-04 |
2023-10-10 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
|
CN105828815B
(zh)
|
2013-12-17 |
2020-03-27 |
勃林格殷格翰动物保健有限公司 |
猫科动物中代谢紊乱的治疗
|
|
WO2015099307A1
(ko)
|
2013-12-26 |
2015-07-02 |
주식회사 포스코 |
연주압연장치 및 방법
|
|
PL3485890T3
(pl)
|
2014-01-23 |
2023-08-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
|
|
KR102662473B1
(ko)
|
2014-04-01 |
2024-05-03 |
베링거잉겔하임베트메디카게엠베하 |
말과 동물에서 대사 장애의 치료
|
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
|
DK3197429T3
(da)
|
2014-09-25 |
2024-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
KR200484486Y1
(ko)
*
|
2016-05-09 |
2017-09-12 |
연세대학교 원주산학협력단 |
시료채취장치
|
|
EP3528800A1
(en)
|
2016-10-19 |
2019-08-28 |
Boehringer Ingelheim International GmbH |
Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
|
|
EP3661937B1
(en)
|
2017-08-01 |
2021-07-28 |
Gilead Sciences, Inc. |
Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
|
|
US12144811B2
(en)
|
2017-11-30 |
2024-11-19 |
Idorsia Pharmaceuticals Ltd |
Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases
|
|
WO2019193572A1
(en)
*
|
2018-04-05 |
2019-10-10 |
Glenmark Pharmaceuticals Limited |
An improved process for the preparation remogliflozin etabonate or pharmaceutically acceptable salt, solvate, hydrate thereof
|
|
AU2019254371A1
(en)
|
2018-04-17 |
2020-10-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
CN112955215B
(zh)
|
2018-10-29 |
2024-05-17 |
勃林格殷格翰国际有限公司 |
吡啶基磺酰胺衍生物、药物组合物及其用途
|
|
CN112955214B
(zh)
|
2018-10-29 |
2024-05-07 |
勃林格殷格翰国际有限公司 |
吡啶基磺酰胺衍生物、药物组合物及其用途
|
|
WO2021105152A1
(en)
|
2019-11-28 |
2021-06-03 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors in the drying-off of non-human mammals
|
|
BR112022016360A2
(pt)
|
2020-02-17 |
2022-10-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
|
|
WO2023006747A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
|
US20240269105A1
(en)
|
2021-07-28 |
2024-08-15 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
|
EP4376829A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
|
WO2023129595A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Obicetrapib and sglt2 inhibitor combination
|
|
CA3256728A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING SGLT-2 INHIBITORS
|
|
TW202500160A
(zh)
|
2023-03-06 |
2025-01-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
用於遞送特別是包含一或多種sglt—2抑制劑之液體醫藥組合物之系統及方法
|
|
EP4701626A1
(en)
|
2023-04-24 |
2026-03-04 |
NewAmsterdam Pharma B.V. |
Amorphous obicetrapib and sglt2 inhibitor combination
|
|
WO2024240632A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|
|
TW202508455A
(zh)
|
2023-05-24 |
2025-03-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
|
|
WO2024254352A1
(en)
*
|
2023-06-06 |
2024-12-12 |
Vogenx |
Sglt1 inhibitor and incretin combinations for treating metabolic disease
|